Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:HROW NASDAQ:INBX NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.11+1.8%$3.32$1.89▼$5.82$1.50B0.626.89 million shs5.17 million shsHROWHarrow$36.19-2.8%$31.00$20.85▼$59.23$1.37B0.41432,278 shs325,350 shsINBXInhibrx Biosciences$23.08+0.0%$16.58$10.80▼$24.75$333.96M-0.04142,922 shs193,206 shsSRPTSarepta Therapeutics$11.93-7.4%$26.12$10.41▼$150.48$1.27B0.4513.25 million shs14.54 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+0.60%+28.72%+36.41%+95.33%+66.78%HROWHarrow+0.78%+3.04%+17.44%+45.75%+56.01%INBXInhibrx Biosciences-0.56%-2.33%+56.30%+88.17%+71.52%SRPTSarepta Therapeutics-3.23%-41.33%-32.09%-78.67%-91.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.3434 of 5 stars3.51.00.00.02.43.30.0HROWHarrow2.6309 of 5 stars3.51.00.00.02.92.50.6INBXInhibrx Biosciences3.1105 of 5 stars0.03.00.04.63.52.51.3SRPTSarepta Therapeutics4.7424 of 5 stars4.12.00.04.22.21.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 3.00Buy$8.7571.23% UpsideHROWHarrow 3.00Buy$63.8376.38% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/ASRPTSarepta Therapeutics 2.11Hold$51.42330.99% UpsideCurrent Analyst Ratings BreakdownLatest INBX, SRPT, ABCL, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight7/24/2025SRPTSarepta TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.007/24/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $48.007/23/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform7/22/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell7/22/2025SRPTSarepta TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell ➝ Sell7/22/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Equal Weight$32.00 ➝ $18.007/22/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$18.007/21/2025SRPTSarepta TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$70.00 ➝ $50.007/21/2025SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/14/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$23.11M65.98N/AN/A$3.58 per share1.43HROWHarrow$212.86M6.24$0.13 per share272.30$1.95 per share18.56INBXInhibrx Biosciences$200K1,670.53$115.40 per share0.20$9.23 per share2.50SRPTSarepta Therapeutics$1.90B0.62$2.26 per share5.29$15.99 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/7/2025 (Estimated)HROWHarrow-$17.48M-$0.56N/A90.48N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.20N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.09N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)Latest INBX, SRPT, ABCL, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025INBXInhibrx Biosciences-$2.92N/AN/AN/AN/AN/A8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17N/AN/AN/A$7.55 millionN/A8/6/2025Q2 2025HROWHarrow$0.01N/AN/AN/A$64.23 millionN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89N/AN/AN/A$530.66 millionN/A5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15HROWHarrow2.010.910.85INBXInhibrx Biosciences1.045.125.12SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%HROWHarrow72.76%INBXInhibrx Biosciences82.46%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%HROWHarrow15.16%INBXInhibrx Biosciences17.09%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableHROWHarrow18036.69 million31.12 millionOptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableINBX, SRPT, ABCL, and HROW HeadlinesRecent News About These CompaniesSarepta Therapeutics Inc (SRPT) Addresses FDA Investigation into Patient Death | SRPT stock news1 hour ago | gurufocus.comSarepta Therapeutics Provides Clarifying Statement on ELEVIDYS | SRPT Stock News2 hours ago | gurufocus.comSarepta falls as FDA plans to investigate death of child who received Elevidys3 hours ago | seekingalpha.comSarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe3 hours ago | msn.comSarepta fails to win EU backing for muscle disorder gene therapy3 hours ago | msn.comFDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy3 hours ago | msn.comSarepta Therapeutics Provides Clarifying Statement on ELEVIDYS3 hours ago | businesswire.comSarepta Therapeutics (SRPT) Stock Falls 9% in After-Hours Trading4 hours ago | gurufocus.comSarepta Therapeutics (SRPT) Faces FDA Scrutiny Over Gene Therapy4 hours ago | gurufocus.comUS FDA investigates third death after treatment with Sarepta's gene therapy Elevidys5 hours ago | reuters.comShareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreJuly 25 at 4:33 PM | globenewswire.comSRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 25 at 4:00 PM | globenewswire.comSarepta Therapeutics (NASDAQ:SRPT) Given New $35.00 Price Target at Jefferies Financial GroupJuly 25 at 1:18 PM | marketbeat.comSarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene TherapyJuly 25 at 12:12 PM | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 10.9% on Analyst DowngradeJuly 25 at 11:53 AM | marketbeat.comWells Fargo & Company Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceJuly 25 at 11:50 AM | marketbeat.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsJuly 25 at 11:43 AM | globenewswire.comLevi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPTJuly 25 at 8:45 AM | prnewswire.comSarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European UnionJuly 25 at 8:34 AM | businesswire.comEU regulator does not recommend approval of Sarepta's muscle disorder gene therapyJuly 25 at 7:13 AM | reuters.comSarepta Therapeutics stock downgraded to Underweight by JPMorganJuly 25 at 4:33 AM | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINBX, SRPT, ABCL, and HROW Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.11 +0.09 (+1.79%) Closing price 04:00 PM EasternExtended Trading$5.13 +0.02 (+0.39%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Harrow NASDAQ:HROW$36.19 -1.05 (-2.82%) Closing price 04:00 PM EasternExtended Trading$36.76 +0.57 (+1.56%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Inhibrx Biosciences NASDAQ:INBX$23.08 +0.01 (+0.04%) Closing price 04:00 PM EasternExtended Trading$23.12 +0.04 (+0.15%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Sarepta Therapeutics NASDAQ:SRPT$11.93 -0.95 (-7.38%) Closing price 04:00 PM EasternExtended Trading$11.45 -0.48 (-4.06%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
